The MS Center at EvergreenHealth is now enrolling for a research trial to study the possible effects of Tecfidera® (dimethyl fumarate) therapy on gut microbiota of patients with Multiple Sclerosis.
This study will also explore the influence of change in gut bacteria on other important aspects of MS, including disease activity and symptomatic issues such as mood.
Do I
qualify?
To be eligible for this study, you must:
Have a confirmed diagnosis of relapsing form of Multiple Sclerosis
- Be at least 18 years old
- Have not taken Tecfidera® (dimethyl fumerate), Fumaderm or other fumerate containing compound
- Be able and willing to comply with the protocol requirements for this study
If you have questions or would like more information on this study, please
contact the study coordinator at 425-899-5369. Find more information online at
This study will also explore the influence of change in gut bacteria on other important aspects of MS, including disease activity and symptomatic issues such as mood.
Do I
To be eligible for this study, you must:
Have a confirmed diagnosis of relapsing form of Multiple Sclerosis
- Be at least 18 years old
- Have not taken Tecfidera® (dimethyl fumerate), Fumaderm or other fumerate containing compound
- Be able and willing to comply with the protocol requirements for this study
If you have questions or would like more information on this study, please
contact the study coordinator at 425-899-5369. Find more information online at
No comments:
Post a Comment